Based on TPX2 and its co-expressed genes, clinical prognostic models were established to predict the prognosis of patients with HCC, which performed better (AUC = 0.801, 0.725, and 0.711 for 1-, 3-, and 5-year survival, respectively) than the prognostic value of TPX2 alone (AUC = 0.73, 0.668, and 0.654 for 1-, 3-, and 5-year survival, respectively). The gene discussed is TPX2; the disease is hepatocellular carcinoma.